文献速递肿瘤 PET/CT甲状腺核医学

99mTc-ADAPT6 首次人体 I 期研究:乳腺癌 HER2 表达可视化支架蛋白探针

Phase I Study of 99mTc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer.
PubMed 文献 · J Nucl Med · 2020-08-17

该首次人体 I 期研究纳入 29 例原发性乳腺癌患者,评估 HER2 特异性 99mTc-ADAPT6 的分布、剂量学与安全性;结果示注射耐受良好、清除快、有效剂量低,500 μg 蛋白量在注射后 2 h 即可优异区分 HER2 阳性与阴性肿瘤。

要点

  • 99mTc-ADAPT6 注射耐受良好,所有蛋白量水平未见不良反应。
  • 500 μg 蛋白量在注射后 2 h 即可优异区分 HER2 阳性与阴性肿瘤。
  • 有效剂量分别为 500 μg 组 0.009 ± 0.002 mSv/MBq、1,000 μg 组 0.010 ± 0.003 mSv/MBq。

核心结论

  • 99mTc-ADAPT6 注射安全且吸收剂量与有效剂量低,500 μg 蛋白量更适合区分 HER2 高表达与低表达肿瘤。

研究设计与样本

  • 首次人体 I 期研究,纳入 29 例原发性乳腺癌患者。
  • 22 例 HER2 阳性(n = 11)或 HER2 阴性(n = 11)组织病理患者随机接受 500 μg(n = 11)或 1,000 μg(n = 11)蛋白量,静脉注射 385 ± 125 MBq 的 99mTc-ADAPT6。
  • 另 7 例队列注射 165 ± 29 MBq(蛋白量 250 μg),仅注射后 2 h 显像。
  • 平面闪烁显像及 SPECT 于注射后 2、4、6、24 h 进行。

主要发现

  • 99mTc-ADAPT6 注射在所有蛋白量水平耐受良好且无不良反应。
  • 99mTc-ADAPT6 从血液及大多数其他组织快速清除,正常器官中肾脏、肝脏和肺聚集最高。
  • 注射后 2 h,500 μg 组 HER2 阳性与阴性肿瘤的肿瘤/对侧乳腺比值分别为 37 ± 19 与 5 ± 2(P < 0.01)。
  • HER2 阳性肿瘤的肿瘤/对侧乳腺比值在 500 μg 组显著高于 250 μg 或 1,000 μg 组(P < 0.05)。

关键数值与推荐

  • 500 μg 与 1,000 μg 蛋白量的有效剂量分别为 0.009 ± 0.002 与 0.010 ± 0.003 mSv/MBq。
  • 注射后 2 h,500 μg 组 HER2 阳性与阴性肿瘤的肿瘤/对侧乳腺比值分别为 37 ± 19 与 5 ± 2(P < 0.01)。
  • HER2 阳性肿瘤的肿瘤/对侧乳腺比值在 500 μg 组显著高于 250 μg 或 1,000 μg 组(P < 0.05)。

临床怎么用

  • 99mTc-ADAPT6 注射安全、有效剂量低,500 μg 蛋白量在注射后 2 h 即可区分 HER2 高表达与低表达肿瘤。
  • 在 PET 显像不易获得地区,99mTc-ADAPT6 有望作为成像探针用于 HER2 靶向治疗患者分层,尚需进一步研究验证。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radionuclide molecular imaging of human epidermal growth factor receptor type 2 (HER2) expression may help to stratify breast and gastroesophageal cancer patients for HER2-targeting therapies. Albumin-binding domain-derived affinity proteins (ADAPTs) are a new type of small (46-59 amino acids) protein useful as probes for molecular imaging. The aim of this first-in-humans study was to evaluate the biodistribution, dosimetry, and safety of the HER2-specific 99mTc-ADAPT6. Methods: Twenty-nine patients with primary breast cancer were included. In 22 patients with HER2-positive (n = 11) or HER2-negative (n = 11) histopathology, an intravenous injection of 385 ± 125 MBq of 99mTc-ADAPT6 was performed, randomized to an injected protein mass of either 500 μg (n = 11) or 1,000 μg (n = 11). Planar scintigraphy followed by SPECT imaging was performed after 2, 4, 6, and 24 h. An additional cohort (n = 7) was injected with 165 ± 29 MBq (injected protein mass, 250 μg), and imaging was performed after 2 h only. Results: Injections of 99mTc-ADAPT6 were well tolerated at all mass levels and not associated with adverse effects. 99mTc-ADAPT6 cleared rapidly from the blood and most other tissues. The normal organs with the highest accumulation were the kidney, liver, and lung. Effective doses were 0.009 ± 0.002 and 0.010 ± 0.003 mSv/MBq for injected protein masses of 500 and 1,000 μg, respectively. Injection of 500 μg resulted in excellent discrimination between HER2-positive and HER2-negative tumors as early as 2 h after injection (tumor-to-contralateral breast ratio, 37 ± 19 vs. 5 ± 2; P < 0.01). The tumor-to-contralateral breast ratios for HER2-positive tumors were significantly (P < 0.05) higher for an injected mass of 500 μg than for either 250 or 1,000 μg. Conclusion: Injections of 99mTc-ADAPT6 are safe and associated with low absorbed and effective doses. A protein dose of 500 μg is preferable for discrimination between tumors with high and low expression of HER2. Further studies are justified to evaluate whether 99mTc-ADAPT6 can be used as an imaging probe to stratify patients for HER2-targeting therapy in areas where PET imaging is not readily available.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bragina O, von Witting E, Garousi J, et al. Phase I Study of 99mTc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer. J Nucl Med. 2020. PMID: 32817142. doi:10.2967/jnumed.120.248799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。